2.15%
7.99%
-6.73%
-1.35%
-37.29%
562.83%
209.32%
AI Spotlight on ARDX
Company Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally.The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia.It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD.
The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd.in China, and Knight Therapeutics, Inc.in Canada for the development and commercialization of tenapanor in their respective territories.
The company was formerly known as Nteryx, Inc.and changed its name to Ardelyx, Inc.in June 2008.
Ardelyx, Inc.was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Market Data
| Last Price | 5.47 |
| Change Percentage | 2.15% |
| Open | 5.35 |
| Previous Close | 5.36 |
| Market Cap ( Millions) | 1297 |
| Volume | 1810130 |
| Year High | 10.13 |
| Year Low | 4.32 |
| M A 50 | 5.2 |
| M A 200 | 6.02 |
Financial Ratios
| FCF Yield | -4.92% |
| Dividend Yield | 0.00% |
| ROE | -46.60% |
| Debt / Equity | 66.01% |
| Net Debt / EBIDTA | -107.54% |
| Price To Book | 8.16 |
| Price Earnings Ratio | -17.8 |
| Price To FCF | -20.33 |
| Price To sales | 5.15 |
| EV / EBITDA | -25.51 |
News
- Jan -30 - Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025
- Jan -14 - Ardelyx (ARDX) Moves 16.0% Higher: Will This Strength Last?
- Jan -13 - Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities
- Jan -06 - Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Nov -24 - Ardelyx Lost The Lawsuit, But The Kidney PATIENT Act Will Save It
- Nov -20 - Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference
- Nov -14 - Ardelyx's Medicare Setback Casts Doubt On Long-Term Viability
- Nov -08 - Ardelyx Responds to District Court Decision Granting Motion to Dismiss
- Nov -05 - Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference
- Nov -01 - Ardelyx, Inc. (ARDX) Q3 2024 Earnings Call Transcript
- Oct -31 - Compared to Estimates, Ardelyx (ARDX) Q3 Earnings: A Look at Key Metrics
- Oct -31 - Ardelyx (ARDX) Reports Break-Even Earnings for Q3
- Oct -31 - Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update
- Oct -28 - Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology's (ACG) Annual Meeting
- Oct -23 - ARDELYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ardelyx, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
- Oct -22 - Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community
- Oct -18 - Here's Why Ardelyx (ARDX) Could be Great Choice for a Bottom Fisher
- Oct -17 - Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024
- Oct -15 - SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadlines - ARDX
- Oct -15 - Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology's Kidney Week
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Biopharmaceutical Products
Expected Growth : 8.97 %
What the company do ?
Ardelyx, Inc. develops and commercializes biopharmaceutical products, including tenapanor, a phosphate binder for treating hyperphosphatemia in patients with end-stage renal disease.
Why we expect these perspectives ?
Ardelyx's biopharmaceutical products are driven by increasing demand for novel treatments, growing prevalence of chronic kidney disease and cardiorenal diseases, and the company's strong pipeline of innovative products, including tenapanor and RDX013. Additionally, strategic partnerships and collaborations are fueling growth, with a focus on expanding into new markets and indications.
Ardelyx, Inc. Products
| Product Range | What is it ? |
|---|---|
| Tenapanor | Tenapanor is a minimally absorbed, oral, gut-restricted inhibitor of the sodium/hydrogen exchanger 3 (NHE3), in development for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic kidney disease (CKD). |
| RDX7675 | RDX7675 is a novel, oral, non-absorbed phosphate binder in development for the treatment of hyperphosphatemia in patients with CKD on dialysis. |
Ardelyx, Inc.'s Porter Forces
Threat Of Substitutes
Ardelyx, Inc. has a moderate threat of substitutes due to the availability of alternative treatments for kidney disease and cardiovascular disease.
Bargaining Power Of Customers
Ardelyx, Inc. has a low bargaining power of customers due to the specialized nature of its products and the lack of alternative options for patients.
Bargaining Power Of Suppliers
Ardelyx, Inc. has a moderate bargaining power of suppliers due to the availability of multiple suppliers for raw materials and manufacturing services.
Threat Of New Entrants
Ardelyx, Inc. has a high threat of new entrants due to the growing demand for kidney disease and cardiovascular disease treatments and the availability of funding for biotech startups.
Intensity Of Rivalry
Ardelyx, Inc. operates in a highly competitive industry with several established players, leading to a high intensity of rivalry.
Strength
Weaknesses
Opportunities
Threats
Capital Structure
| Value | |
|---|---|
| Debt Weight | 25.13% |
| Debt Cost | 8.26% |
| Equity Weight | 74.87% |
| Equity Cost | 8.26% |
| WACC | 8.26% |
| Leverage | 33.56% |
Ardelyx, Inc. : Quality Control
Ardelyx, Inc. passed 2 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| LGND | Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which … |
| PBYI | Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 … |
| AMLX | Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax … |
| ITOS | Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the … |
| APLT | Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Ligand Pharmaceuticals
A-Score
1-Year Total Return ->
🥈
Applied Therapeutics
A-Score
1-Year Total Return ->
🥉
Puma Biotechnology
A-Score
1-Year Total Return ->
4
Amylyx Pharmaceuticals
A-Score
1-Year Total Return ->
5
iTeos Therapeutics
A-Score
1-Year Total Return ->
6
